GeneDx goes for nullification of 11 Myriad Genetics patents; Harvard team creates cheap handheld Dx device;

> GeneDx wants the U.S. Patent and Trademark Office to nullify 11 patents held by Myriad Genetics ($MYGN) that involve predicting cancer risk. Story (reg. req.)

> MDxHealth says a new clinical study shows its ConfirmMDx molecular diagnostic test can spot a biomarker connected to the risk of recurrence for early-stage prostate cancer patients. Release

> Harvard researchers have developed an inexpensive handheld diagnostic device for use in the world's poorest regions that can monitor diabetes, detect malaria and analyze drinking water. Story

> Global Cancer Diagnostics in Arizona is gearing up to launch an early-detection lung cancer blood test. Story

> Two scientists from Northwestern University said they've identified a new biomarker in an aggressive form of breast cancer that resists many kinds of chemotherapy. Item